In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Bolt Biotherapeutics, with a price target of $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Robert Burns has given his Buy rating due to a combination of factors related to both Bolt Biotherapeutics’ lead program and its financial position. He highlights BDC-4182 as a differentiated Claudin 18.2-targeted ISAC that uses a TLR7/8 agonist payload rather than a traditional cytotoxic agent, with preclinical data indicating stronger tumor control than standard ADCs, activity in low-antigen settings, and complete regressions in cold tumors.
Burns also notes that BDC-4182 is already in a Phase 1/2 trial in later-line gastric and gastroesophageal cancer, with first clinical readouts anticipated in 3Q26, which can be a key catalyst. On the financial side, recent quarterly results were in line with expectations, projected 2026 losses have narrowed, and the current cash balance is expected to fund operations into 2027, supporting ongoing development. Based on a DCF analysis that assumes a prudent probability of launch and standard discount and growth rates, he arrives at a $7 price target, while acknowledging clinical, regulatory, competitive, and financing risks.
According to TipRanks, Burns is a 5-star analyst with an average return of 16.2% and a 46.87% success rate. Burns covers the Healthcare sector, focusing on stocks such as Exelixis, Karyopharm Therapeutics, and Cogent Biosciences.